These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23954890)

  • 1. The biology and clinical impact of genetic lesions in myeloid malignancies.
    Lindsley RC; Ebert BL
    Blood; 2013 Nov; 122(23):3741-8. PubMed ID: 23954890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cohesin mutations in myeloid malignancies.
    Jann JC; Tothova Z
    Blood; 2021 Aug; 138(8):649-661. PubMed ID: 34157074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic biomarkers in myeloid malignancies.
    Matynia AP; Szankasi P; Shen W; Kelley TW
    Arch Pathol Lab Med; 2015 May; 139(5):594-601. PubMed ID: 25152312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
    Patel U; Luthra R; Medeiros LJ; Patel KP
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications.
    Malcovati L; Ambaglio I; Elena C
    Curr Opin Oncol; 2015 Nov; 27(6):551-9. PubMed ID: 26352542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of del(20q) in patients with hematological malignancies.
    Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
    Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
    Ungerstedt JS
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.
    McKerrell T; Moreno T; Ponstingl H; Bolli N; Dias JM; Tischler G; Colonna V; Manasse B; Bench A; Bloxham D; Herman B; Fletcher D; Park N; Quail MA; Manes N; Hodkinson C; Baxter J; Sierra J; Foukaneli T; Warren AJ; Chi J; Costeas P; Rad R; Huntly B; Grove C; Ning Z; Tyler-Smith C; Varela I; Scott M; Nomdedeu J; Mustonen V; Vassiliou GS
    Blood; 2016 Jul; 128(1):e1-9. PubMed ID: 27121471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of myeloid malignancies: pathogenetic and clinical implications.
    Fröhling S; Scholl C; Gilliland DG; Levine RL
    J Clin Oncol; 2005 Sep; 23(26):6285-95. PubMed ID: 16155011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohesin mutations in myeloid malignancies made simple.
    Viny AD; Levine RL
    Curr Opin Hematol; 2018 Mar; 25(2):61-66. PubMed ID: 29278534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 7q22 deletion in myeloid malignancies: be attentive to the design of the FISH probe.
    Struski S; Luquet I
    Ann Biol Clin (Paris); 2019 Apr; 77(2):229-230. PubMed ID: 30907375
    [No Abstract]   [Full Text] [Related]  

  • 13. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic basis of myelodysplastic syndromes.
    Ogawa S
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(3):107-121. PubMed ID: 32161209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic predisposition to pediatric myeloid malignancies].
    Muramatsu H
    Rinsho Ketsueki; 2016 Jun; 57(6):730-5. PubMed ID: 27384852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci.
    Carraway HE; LaFramboise T
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101191. PubMed ID: 33038980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic deregulation in myeloid malignancies.
    Huang HT; Figueroa ME
    Blood; 2021 Aug; 138(8):613-624. PubMed ID: 34436526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of mutations in epigenetic regulators in myeloid malignancies.
    Woods BA; Levine RL
    Immunol Rev; 2015 Jan; 263(1):22-35. PubMed ID: 25510269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2 and Beyond: Mutational Study of JAK2V617 in Myeloproliferative Disorders and Haematological Malignancies in Kashmiri population.
    Syeed N
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3611-3615. PubMed ID: 31870101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis of myeloid malignancies.
    Kitamura T; Inoue D; Okochi-Watanabe N; Kato N; Komeno Y; Lu Y; Enomoto Y; Doki N; Uchida T; Kagiyama Y; Togami K; Kawabata KC; Nagase R; Horikawa S; Hayashi Y; Saika M; Fukuyama T; Izawa K; Oki T; Nakahara F; Kitaura J
    Proc Jpn Acad Ser B Phys Biol Sci; 2014; 90(10):389-404. PubMed ID: 25504228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.